Evidence map›Paper›PMID 27156652›Full record

ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2016

Predicting distant failure in early stage NSCLC treated with SBRT using clinical parameters.

Zhiguo Zhou, Michael Folkert, Nathan Cannon, Puneeth Iyengar, Kenneth Westover, Yuanyuan Zhang, Hak Choy, Robert Timmerman, Jingsheng Yan, Xian-J Xie and 2 more

Abstract read
In one paragraph

Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Multicentric development and evaluation of [European journal of nuclear medicine and molecular imaging · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhiguo ZhouDepartment of Radiation Oncology, UT Southwestern Medical Center, Dallas, United States.
Michael FolkertDepartment of Radiation Oncology, UT Southwestern Medical Center, Dallas, United States.
Nathan CannonDepartment of Radiation Oncology, UT Southwestern Medical Center, Dallas, United States.
Puneeth IyengarDepartment of Radiation Oncology, UT Southwestern Medical Center, Dallas, United States.
Kenneth WestoverDepartment of Radiation Oncology, UT Southwestern Medical Center, Dallas, United States.
Yuanyuan ZhangDepartment of Radiation Oncology, UT Southwestern Medical Center, Dallas, United States.
Hak ChoyDepartment of Radiation Oncology, UT Southwestern Medical Center, Dallas, United States.
Robert TimmermanDepartment of Radiation Oncology, UT Southwestern Medical Center, Dallas, United States.
Jingsheng YanDepartment of Clinical Science, UT Southwestern Medical Center, Dallas, United States.
Xian-J XieDepartment of Clinical Science, UT Southwestern Medical Center, Dallas, United States.
Steve JiangDepartment of Radiation Oncology, UT Southwestern Medical Center, Dallas, United States.
Jing WangDepartment of Radiation Oncology, UT Southwestern Medical Center, Dallas, United States. Electronic address: jing.wang@utsouthwestern.edu.

Funding

Next generation 4D-CBCT for lung cancer radiation therapyR01EB020366 · NIBIB · UT SOUTHWESTERN MEDICAL CENTER · PI WANG, JING · 2015 to 2018
$1.4M
NIBIB NIH HHS R01 EB020366
6 · The paper itself

Abstract

PURPOSE/

objectiveThe aim of this study is to predict early distant failure in early stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) using clinical parameters by machine learning algorithms. MATERIALS/

methodsThe dataset used in this work includes 81 early stage NSCLC patients with at least 6months of follow-up who underwent SBRT between 2006 and 2012 at a single institution. The clinical parameters (n=18) for each patient include demographic parameters, tumor characteristics, treatment fraction schemes, and pretreatment medications. Three predictive models were constructed based on different machine learning algorithms: (1) artificial neural network (ANN), (2) logistic regression (LR) and (3) support vector machine (SVM). Furthermore, to select an optimal clinical parameter set for the model construction, three strategies were adopted: (1) clonal selection algorithm (CSA) based selection strategy; (2) sequential forward selection (SFS) method; and (3) statistical analysis (SA) based strategy. 5-cross-validation is used to validate the performance of each predictive model. The accuracy was assessed by area under the receiver operating characteristic (ROC) curve (AUC), sensitivity and specificity of the system was also evaluated.

resultsThe AUCs for ANN, LR and SVM were 0.75, 0.73, and 0.80, respectively. The sensitivity values for ANN, LR and SVM were 71.2%, 72.9% and 83.1%, while the specificity values for ANN, LR and SVM were 59.1%, 63.6% and 63.6%, respectively. Meanwhile, the CSA based strategy outperformed SFS and SA in terms of AUC, sensitivity and specificity.

conclusionsBased on clinical parameters, the SVM with the CSA optimal parameter set selection strategy achieves better performance than other strategies for predicting distant failure in lung SBRT patients.

Indexed as

RadiosurgeryAgedAlgorithmsArea Under CurveCarcinoma, Non-Small-Cell LungFemaleHumansLogistic ModelsLung NeoplasmsMaleMiddle AgedNeoplasm StagingNeural Networks, ComputerTreatment FailureClinical parameterDistant failureFeature selectionMachine learningSBRT

Identifiers

PMID27156652
PMCPMC4930894

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.